Lands End Inc
Change company Symbol lookup
Select an option...
LE Lands End Inc
WING Wingstop Inc
PUMP ProPetro Holding Corp
CHK Chesapeake Energy Corp
SALM Salem Media Group Inc
UGAZ VelocityShares 3x Long Natural Gas ETN Linked to the S&P GSCI? Natural Gas Index ER
UBSI United Bankshares Inc
LTM LATAM Airlines Group SA
TRGP Targa Resources Corp
PFE Pfizer Inc
Go

Consumer Discretionary : Internet & Direct Marketing Retail | Small Cap Growth
Company profile

Lands' End, Inc. (Lands' End) is a multi-channel retailer of casual clothing, accessories and footwear, as well as home products. The Company operates through two segments: Direct and Retail. The Company offers products through catalogs, online at www.landsend.com. The Direct segment sells products through the Company's e-commerce Websites, international Websites and direct mail catalogs. The Retail segment sells products and services through Lands' End Shops at Sears across the United States, the Company's standalone Lands' End Inlet stores and international shop-in-shops. The Company's product categories include Apparel and Non-apparel. The Non-apparel category offers accessories, footwear and home goods. The Company provides embroidery, monogramming, gift wrapping, shipping and other services. In addition, the Company offers sheets and pillowcases, duvet covers and comforters, blankets and throws, mattress pads, towels, rugs and mats, school uniforms and shower curtains.

Closing Price
$7.22
Day's Change
0.94 (14.97%)
Bid
--
Ask
--
B/A Size
--
Day's High
7.44
Day's Low
6.37
Volume
(Heavy Day)
Volume:
554,809

10-day average volume:
336,895
554,809

First data from trial of Moderna vaccine candidate for coronavirus could come by June: Evercore

2:54 pm ET March 16, 2020 (MarketWatch)
Print

The first set of immunogenicity data from the first trial of a potential vaccine to treat the coronavirus that causes COVID-19 could come as early as June, according to Evercore analyst Umer Ruffat. The National Institutes of Health is funding the trial of a vaccine developed by Moderna Inc. (MRNA) that kicked off Monday, and is taking place at the Kaiser Permanente Washington Health Research Institute in Seattle. "Management said they expect to dose first patients very shortly (they've screened a bunch already)," Raffat wrote in a Monday note to clients. Moderna management told Evercore that it could have 10 million doses ready by summer. "Moderna used experience from other trials of its vaccines to inform these doses (because other vaccines have shown immunogenicity at doses as low as 10 mcg)," said the analyst. Moderna shares rose 27% Monday.

-Ciara Linnane; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

March 16, 2020 14:54 ET (18:54 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.